VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DNTHDianthus Therapeutics, Inc.
$86.98$3.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
DNTH logo

Dianthus Therapeutics, Inc.

DNTH
NASDAQ · Immunology Biotech
$86.98
At close - Nov 17, 4:00 PM EST - USD
Market Cap$3.63B
P/E-125.3x
52W High$117.88
Volume548.49K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Clinical Cash Burn Outpaces Shrinking Revenue Base

Dianthus Therapeutics' legacy revenue has contracted from $2.2M in 2024Q3 to $1.2M in 2026Q3, while R&D expense has climbed to $45.6M per quarter, pushing operating losses to -$58.5M and free cash flow to -$50.7M.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

DNTH price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-409% Peers

P/E is 409% below peer median

03

Market leadership

RS 90 · Leader

High momentum (Outperforming 90% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 4

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
DNTH+119.20%
S&P 500 (^GSPC)+7.21%
1-Year Return
DNTH+110.35%
S&P 500 (^GSPC)+10.03%
3-Year Return
DNTH+666.34%
S&P 500 (^GSPC)+56.98%
5-Year Return
DNTH-22.45%
S&P 500 (^GSPC)+56.51%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-125.3x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-125.3x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.26-98.6%
Base (Fair)$92.79+1.1%
Bull$1.31-98.5%
$1.26 Bear$92.79 Base$1.31 Bull
Current Market Price: $86.98
Trades at a 6.3% discount to Base DCF ($92.79)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$2M-67.3% YoY
Net income FY25
-$162M-91.1% YoY
Free cash flow FY25
-$129M-65.1% YoY
Operating margin FY25
-8739.3%-7105.6 pts YoY
ROIC (FY25)-34.4%
Avg ROIC 5Y-42.2%
ROE (TTM)-3.9%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 4, 2026
-$0.81+14.2%
vs -$0.94
$1M+162.5%
vs $460,928
Q3 2026
Aug 4, 2026
-$0.90-6.3%
vs -$0.85
$761,000+156.1%
vs $297,182
Q2 2026
May 5, 2026
-$0.85+27.4%
vs -$1.17
$463,000+14.7%
vs $403,615
Q2 2026
Mar 9, 2026
-$1.43-45.9%
vs -$0.98
$284,000-48.6%
vs $552,231
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·1d ago
Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

Defense World·2d ago
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,118,555.02 in Stock

Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Ryan Savitz sold 100,713 shares of the business's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02. Following the transaction, the executive vice president owned 29,276 shares in the company, valued

Zacks Investment Research·Nov 9, 2026
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?

The mean of analysts' price targets for Dianthus Therapeutics, Inc. (DNTH) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research·Nov 4, 2026
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.

Filtered for Dianthus Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark DNTH against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Dianthus Therapeutics, Inc. (DNTH)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
DNTH logoDNTHDianthus Therapeutics, Inc.Current
$86.98$3.63B-125.35-67.35%-1463.83%-3.87%—
ALXO logoALXOALX Oncology Holdings Inc.
$1.01$135.24M-1.76——-73.35%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
RCUS logoRCUSArcus Biosciences, Inc.
$16.39$2.06B-4.69-4.26%-445%-90.04%—
OMAB logoOMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V.
$107.78$5.2B17.605.91%31.67%49.07%4.66%
VKTX logoVKTXViking Therapeutics, Inc.
$26.88$3.14B-5.06——-117.35%—

Compare DNTH vs Peers

Dianthus Therapeutics, Inc. (DNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALXO

Most directly comparable listed peer for DNTH.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare DNTH against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALXO, IMVT, RCUS, OMAB

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

DNTH SEC Filings & Documents

Dianthus Therapeutics, Inc. (DNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 4, 2026·SEC

Material company update

Aug 4, 2026·SEC

Material company update

Jun 12, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 9, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 4, 2026·SEC

FY 2026

Aug 4, 2026·SEC

FY 2026

May 5, 2026·SEC

Get notified when DNTH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

DNTH Frequently Asked Questions

Dianthus Therapeutics, Inc. (DNTH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Dianthus Therapeutics, Inc.'s revenue?

Dianthus Therapeutics, Inc. (DNTH) reported $2.7M in revenue over the trailing twelve months. Revenue was $2.0M in fiscal year 2025.

How fast is Dianthus Therapeutics, Inc. growing?

Dianthus Therapeutics, Inc. (DNTH) revenue fell by 11.7% over the trailing twelve months, compared with the twelve months before.

Is DNTH profitable?

No. Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $39.8M over the trailing twelve months.

Dividend & Returns
What is DNTH's return on equity?

Dianthus Therapeutics, Inc. (DNTH) had a return on equity (ROE) of -3.9% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Dianthus Therapeutics, Inc.'s free cash flow?

Dianthus Therapeutics, Inc. (DNTH) had negative free cash flow of $175.9M over the trailing twelve months.

What if you invested $1,000 in DNTH back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →